Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Jackson-Spence

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Clinical Genitourinary Cancer|April 14, 2024
NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsMatthew Young, Jose C Tapia, Bernadett Szabados, et al.
Future Oncology (London, England)|April 21, 2023
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgeryFrancesca Jackson-Spence, Charlotte Toms, Luke Furtado O'Mahony, et al.
Expert Review of Anticancer Therapy|August 5, 2025
Established and emerging biomarkers approaches in urothelial carcinomaSara Coca Membribes, Elizabeth Nally, Francesca Jackson-Spence, et al.
Lancet (London, England)|July 21, 2024
Renal cell carcinomaMatthew Young, Francesca Jackson-Spence, Luis Beltran, et al.
European Urology Focus|June 2, 2024
Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?Elizabeth Nally, Matthew Young, Connor Wells, et al.
Cancers|March 14, 2026
VEGF-TKI Outcomes in Metastatic Renal Cell Carcinoma According to Prior Immune Checkpoint Inhibitor or VEGF-TKI: A Scoping Review and Exploratory AnalysisElizabeth Nally, Agne Jovaisaite, Sara Coca Membribes, et al.
World Journal of Urology|July 24, 2024
Systemic therapies and primary tumour downsizing in renal cell carcinoma: a real-world comparison of anti-angiogenic and immune checkpoint inhibition regimensLeo Jurascheck Bickley, Yu-Hsuen Yang, Francesca Jackson-Spence, et al.
BJU International|June 9, 2017
Centralisation of radical cystectomies for bladder cancer in England, a decade on from the 'Improving Outcomes Guidance': the case for super centralisationMehran Afshar, Henry Goodfellow, Francesca Jackson-Spence, et al.
Cancer Medicine|June 19, 2026
Characteristics of Patients With Advanced or Metastatic Urothelial Cancer Unable to Complete Six Cycles ChemotherapyFrancesca Jackson-Spence, Domiziana Aspden, Vishwani Chauhan, et al.
Clinical Genitourinary Cancer|March 15, 2023
Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective StudyYu-Hsuen Yang, Sonam Ansel, Aafke Meerveld-Eggink, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Clinical Genitourinary Cancer|April 14, 2024
NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsMatthew Young, Jose C Tapia, Bernadett Szabados, et al.
Future Oncology (London, England)|April 21, 2023
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgeryFrancesca Jackson-Spence, Charlotte Toms, Luke Furtado O'Mahony, et al.
Expert Review of Anticancer Therapy|August 5, 2025
Established and emerging biomarkers approaches in urothelial carcinomaSara Coca Membribes, Elizabeth Nally, Francesca Jackson-Spence, et al.
Lancet (London, England)|July 21, 2024
Renal cell carcinomaMatthew Young, Francesca Jackson-Spence, Luis Beltran, et al.
European Urology Focus|June 2, 2024
Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?Elizabeth Nally, Matthew Young, Connor Wells, et al.
Cancers|March 14, 2026
VEGF-TKI Outcomes in Metastatic Renal Cell Carcinoma According to Prior Immune Checkpoint Inhibitor or VEGF-TKI: A Scoping Review and Exploratory AnalysisElizabeth Nally, Agne Jovaisaite, Sara Coca Membribes, et al.
World Journal of Urology|July 24, 2024
Systemic therapies and primary tumour downsizing in renal cell carcinoma: a real-world comparison of anti-angiogenic and immune checkpoint inhibition regimensLeo Jurascheck Bickley, Yu-Hsuen Yang, Francesca Jackson-Spence, et al.
BJU International|June 9, 2017
Centralisation of radical cystectomies for bladder cancer in England, a decade on from the 'Improving Outcomes Guidance': the case for super centralisationMehran Afshar, Henry Goodfellow, Francesca Jackson-Spence, et al.
Cancer Medicine|June 19, 2026
Characteristics of Patients With Advanced or Metastatic Urothelial Cancer Unable to Complete Six Cycles ChemotherapyFrancesca Jackson-Spence, Domiziana Aspden, Vishwani Chauhan, et al.
Clinical Genitourinary Cancer|March 15, 2023
Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective StudyYu-Hsuen Yang, Sonam Ansel, Aafke Meerveld-Eggink, et al.
Pageof 3